Analytica Expands Clinical Indication for Its Unique Pelvic Floor Exercise Technology

Analytica Limited (ASX:ALT) has received clearance from the Australian Therapeutic Goods Administration for the expanded clinical indication for its PeriCoach System to assist in the conservative treatment of Pelvic Organ Prolapse (POP). The PeriCoach system with its patent protected force sensing technology assists women to properly perform pelvic floor exercises. The expanded clinical indication for PeriCoach now includes targeted resolution of symptoms for mild to moderate POP, urinary incontinence and sexual wellness. Data suggests that 50% of women that have given birth have some degree of POP and half of women over 50 complain of prolapse symptoms. Estimates state women have a lifetime risk of up to 12% of undergoing a surgical intervention, with a re-operation rate of nearly 20%. Read more.

Source: Proactiveinvestors Australia, May 2, 2018

FDA Approves OTC Availability of PeriCoach, an At-home Pelvic Floor Trainer Device

DENVER – Analytica on Wednesday announced that the U.S. Food and Drug Administration has approved the PeriCoach at-home pelvic floor trainer device and smartphone app as an over-the-counter treatment for mild, moderate and stress urinary incontinence and urge incontinence. Pelvic floor muscle exercise is recommended as first line non-pharmacologic treatment for the millions of women – estimated at one in three – who suffer from urinary incontinence. Read more.

Source: Drug Store News, July 13, 2016